Conduct of clinical trials with and supply of medicinal products for human use containing or consisting of genetically modified organisms intended to treat or pent coronavirus disease
Health65%★
- title/description contains "disease"
Importance Score
High importanceWhy this vote stands out:
- ✓Main vote
- ✓Legislative procedure
- ✓Some political group division
- ✓High participation
- ✓Many MEPs voted against their group
Show full breakdown
Methodology: importance-v0.1 · The Importance Score is a prioritisation indicator. It does not judge whether a vote is good or bad.
What was this vote about?
This vote concerned “Conduct of clinical trials with and supply of medicinal products for human use containing or consisting of genetically modified organisms intended to treat or pent coronavirus disease”. EPP, S&D, Renew, PfE, ECR and NI voted mostly in favour, while ESN voted mostly against. Greens-EFA and Left mostly abstained. The motion was adopted by a comfortable margin (505 for, 67 against, 109 abstentions).
Automated summary generated from official vote metadata and observed voting patterns. Not a legal interpretation.
Why it matters
This is a main (final) vote on a dossier — the decisive moment where the European Parliament adopts or rejects a legislative or political text. These are the votes that most directly shape EU law and policy, and the ones citizens and journalists should watch most closely.
Result analysis
By political group
Country angle
- Italy60
- Germany51
- Poland48
- Spain45
- France37
None.
- Cyprus
- France
Full breakdown by all countries
Individual MEP positions
Loading individual positions…